国产注射用重组人尿激酶原治疗急性心肌梗死疗效观察

Therapeutic effect of recombinant prourokinase on the patients with acute myocardial infarction

目的 :观察国产注射用重组人尿激酶原 (rhPro-UK)治疗急性心肌梗死 (AMI)的效果和副作用。方法 :将31例发病 6h内的AMI患者随机分为rhPro -UK组 (n =16 )和尿激酶 (UK)组 (n =15 )。rhPro -UK组取rhPro -UK2 0mg溶于 10ml生理盐水中 3min内静脉注射 ,另取 2 0mg溶于 90ml生理盐水中 30min内静脉滴注完毕。尿激酶组取UK 15 0万单位溶于 10 0ml生理盐水中 30min内静脉滴注完毕。在溶栓 90min时进行选择性冠状动脉造影 ,评价梗死相关动脉开通情况。评价出血并发症以及生化指标变化情况。结果 :rhPro -UK组总的梗死相关动脉开通率为 74 .9% ,UK组为 6 6 .7% (P =0 .0 4 1)。rhPro -UK组无颅内出血 ,UK组有 1例致命性颅内出血 ;其余出血并发症以及生化指标变化情况 2组差异无统计学意义。结论 :AMI时应用国产rhPro -UK进行静脉溶栓成功率高 ,使用安全 。

Aim: To investigate the therapeutic effect and side effect of recombinant prourokinase (rhPro-UK) on the patients with acute myocardial infarction. Methods: A total of 31 cases of acute myocardial infarction treated by thrombolytic agents within 6 hours after onset were divided randomly into rhPro-UK group(n=16) and urokinase (UK) group(n=15). In rhPro-UK group, 20 mg rhPro-UK was used by intravenous injection within 3 minutes, then 20mg rhPro-UK was injected into vein within 30 minutes. In UK group, 1.5 million units UK was used by intravenous injection within 30 minutes. The dilation of infarct-related coronary artery was evaluated by coronary angiography. Results: The dilation rates were 74.9% in rhPro-UK group and 66.7% in UK group,respectively(P=0.041). There was no intracranial hemorrhage in rhPro-UK group. However in UK group, one patient experienced intracranial hemorrhage. Conclusion: rhPro-UK is safe and effective for the patients with acute myocardial infarction.